Fludarabine
Recurrent T Acute Lymphoblastic Leukemia
Children's Oncology GroupSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
79 Active assets in the Recurrent T Acute Lymphoblastic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VINCRISTINE SULFATE Children's Oncology Group | Phase 3 | BB |
Daunorubicin SWOG Cancer Research Network | Phase 3 | BB |
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT) University of Washington | Phase 3 | BB |
PEGASPARGASE Children's Oncology Group | Phase 3 | BB |
MERCAPTOPURINE ANHYDROUS SWOG Cancer Research Network | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →